GlassScriptPhysician profile
Ashley Miller
NPI 1033594114
$2,769.52
in general payments reported to CMS, 2019-2025
33 companies · $55.17 in 2025
The $55.17 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,678 · 2022: $804 · 2023: $232 · 2025: $55.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $436.58 | 2021 | |
| Abbott Laboratories | $354.69 | 2021-2023 | Proclaim |
| Boston Scientific Corporation | $291.38 | 2021-2025 | General - Pain Management |
| Abbvie INC. | $283.70 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.90 | 2021-2022 | |
| Saluda Medical Americas, INC. | $117.58 | 2022 | |
| Upsher-Smith Laboratories LLC | $107.68 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $106.98 | 2021-2025 | Xtampza, Belbuca |
| Arbor Pharmaceuticals, INC. | $66.29 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.96 | 2022 | |
| Amgen INC. | $59.56 | 2021-2022 | |
| Protega Pharmaceutials INC | $58.00 | 2022-2023 | Roxybond |
| Grt US Holding, INC. | $56.31 | 2021-2022 | |
| Lilly USA, LLC | $55.06 | 2022-2023 | Emgality |
| Novartis Pharmaceuticals Corporation | $54.73 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $52.27 | 2022 | |
| Allergan, INC. | $50.44 | 2021-2022 | |
| Redhill Biopharma INC. | $50.36 | 2021 | |
| Ibsa Pharma INC. | $44.82 | 2021 | |
| Lundbeck LLC | $44.02 | 2022 | |
| Bioventus LLC | $31.15 | 2022 | |
| Azurity Pharmaceuticals, INC. | $30.24 | 2023 | Horizant |
| Merz Pharmaceuticals, LLC | $25.78 | 2022 | |
| Organogenesis INC. | $21.62 | 2021 | |
| Almatica Pharma LLC | $19.45 | 2021 | |
| Forte Bio-Pharma LLC | $18.79 | 2023 | Prolate, Nalocet |
| Impel Pharmaceuticals INC. | $17.51 | 2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $16.82 | 2021 | |
| Spr Therapeutics, INC | $16.70 | 2022 | |
| Pfizer INC. | $15.16 | 2023 | |
| Scilex Pharmaceuticals INC. | $13.48 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.79 | 2021 | |
| Currax Pharmaceuticals LLC | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.